Breaking News

Phosphorex to Expand Its Manufacturing Services with Investment from Ampersand

Will build out its 30,000 square foot facility and establish new cGMP manufacturing capabilities.

Author Image

By: Charlie Sternberg

Associate Editor

Phosphorex, a drug delivery-focused contract development and manufacturing organization providing microspheres and polymer and lipid nanoparticles, has announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.   Headquartered approximately 30 minutes west of Boston, Phosphorex’s formulation development and analytical laboratories offer a range of customized production services, supporting asset...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters